Capricor shares rise as FDA decision nears; no Q3 revenue and $42.7M loss
FROM THE WIRE · SEEKINGALPHA.COM
Capricor reports no Q3 revenue and a $42.7 million loss, missing EPS estimates by $0.31 a share; FDA decision on deramiocel is due Nov.
Read at the source ↗MARKET IMPACTNEUTRAL✦ News Impact agent estimateTone: neutralThe FDA decision on deramiocel, due in November, is a key catalyst for the stock.AI-generated summary
✦ IN BRIEF · AIAI-generated summary
- 01Capricor reported no revenue in the third quarter.
- 02The loss was $42.7 million, missing EPS estimates by $0.31 per share.
- 03The FDA decision on deramiocel is due in November.
NEWS IMPACT AND MARKET REACTIONChange since the story · reference
Impact and summary are estimates by the News Impact AI agent, not financial advice.Open in Markets